Premnath V | Drugs Monitor

(13 Sep 2020) Hydroxychloroquine- Early intervention with HCQ-based therapy is associated with lower adverse clinical outcomes

September 15, 2020

The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study https://www.medrxiv.org/content/10.1101/2020.09.09.20184143v1 Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever clinics during the study period, 5,541 had verified clinical… Continue reading "(13 Sep 2020) Hydroxychloroquine- Early intervention with HCQ-based therapy is associated with lower adverse clinical outcomes"

(13 Sep 2020) Anakinra & Tocilizumab- associated with improved clinical outcomes

September 15, 2020

Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia https://www.medrxiv.org/content/10.1101/2020.09.11.20192401v1 84 consecutive patients who received either treatment (51 in the Anakinra/ IVIG group and 33 in the Tocilizumab group) were retrospectively studied. Baseline inflammatory markers were similar… Continue reading "(13 Sep 2020) Anakinra & Tocilizumab- associated with improved clinical outcomes"

(12 Sep 2020) Tocilizumab- early dosing associated with increased survival

September 15, 2020

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 https://doi.org/10.1111/cts.12894 This was a multi-center study with data collected by chart review both retrospectively and concurrently. 145 patients were evaluated. The average age was 58.1 years, 64% were… Continue reading "(12 Sep 2020) Tocilizumab- early dosing associated with increased survival"

(10 Sep 2020) Tocilizumab- combined with steroids increases survival rate

September 11, 2020

COMBINATION OF TOCILIZUMAB AND STEROIDS TO IMPROVE MORTALITY IN PATIENTS WITH SEVERE COVID-19 INFECTION: A SPANISH, MULTICENTER, COHORT STUDY https://www.medrxiv.org/content/10.1101/2020.09.07.20189357v2.full.pdf During the study period, 506 patients with severe COVID-19 fulfilled inclusion criteria. Among them, 268 were treated with tocilizumab and… Continue reading "(10 Sep 2020) Tocilizumab- combined with steroids increases survival rate"

(08 Sep 2020) Tocilizumab- effective in managing early CRS related to COVID-19 disease

September 11, 2020

Tocilizumab for severe COVID-19 related illness – A community academic medical center experience https://doi.org/10.1016/j.cytox.2020.100035 In an academic community medical center,31 patients with anti-IL-6/IL-6-R agents including 12 who had already been intubated were treated with TCZ. Overall, 27 (87%) patients are… Continue reading "(08 Sep 2020) Tocilizumab- effective in managing early CRS related to COVID-19 disease"

(07 Sep 2020) LMW Heparin- D-dimer, and CRP levels were significantly improved in the LMWH group

September 9, 2020

The impact of the “low molecular weight heparin” administration on the clinical course of COVID-19 disease https://doi.org/10.3906/sag-2006-184 This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19. Participants… Continue reading "(07 Sep 2020) LMW Heparin- D-dimer, and CRP levels were significantly improved in the LMWH group"

(07 Sep 2020) Azithromycin- No benefit seen with routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19

September 7, 2020

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial https://doi.org/10.1016/S0140-6736(20)31862-6 An open-label, randomised clinical trial (NCT04321278) at… Continue reading "(07 Sep 2020) Azithromycin- No benefit seen with routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19"

(04 Sep 2020) Corticosteroids-early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes

September 5, 2020

Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study https://doi.org/10.1007/s40121-020-00332-3 A retrospective study based on propensity score matching was designed to explore the effects of corticosteroids. Primary outcomes included the rate… Continue reading "(04 Sep 2020) Corticosteroids-early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes"

(03 Sep 2020) Dexamethasone- statistically significant increase in the number of ventilator-free days

September 4, 2020

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial https://doi.org/10.1001/jama.2020.17021 A multicenter, randomized, open-label, clinical trial (NCT04327401) was conducted in 41 intensive care units… Continue reading "(03 Sep 2020) Dexamethasone- statistically significant increase in the number of ventilator-free days"

(02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression

September 4, 2020

Dual-Histamine Receptor Blockade with Cetirizine – Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients https://doi.org/10.1016/j.pupt.2020.101942 A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a… Continue reading "(02 Sep 2020) Famotidine- in combination with cetrizine exhibited beneficial reductions in inpatient mortality and symptom progression"

Author: Premnath V